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Pathogenesisls have been developed for the study of severe acute respiratory syndrome
coronavirus (SARS-CoV) replication and pathogenesis. Syrian golden hamsters are among the best small
animal models, though little clinical illness and no mortality are observed after virus infection. Cyclopho-
sphamide was used to immunosuppress hamsters leading to a prolonged disease course and higher mortality
after SARS-CoV infection. In addition, there was a signiﬁcant weight loss, expanded tissue tropism, and
increased viral pathology in the lung, heart, kidney, and nasal turbinate tissues. Infection with recombinant
SARS-CoV viruses bearing disruptions in the gene 7 coding region showed no signiﬁcant change in
replication kinetics, tissue tropism, morbidity, or mortality suggesting that the ORF7a (7a) and ORF7b (7b)
proteins are not required for virus replication in immunosuppressed hamsters. This modiﬁed hamster model
may provide a useful tool for SARS-CoV pathogenesis studies, evaluation of antiviral therapy, and analysis of
additional SARS-CoV mutants.
© 2008 Elsevier Inc. All rights reserved.IntroductionThe severe acute respiratory syndrome coronavirus (SARS-CoV)
emerged as the causative agent of a severe, atypical pneumonia in
November, 2002. The disease ﬁrst appeared in the Guangdong
province of southeast China and rapidly spread to Hong Kong, Taiwan,
Singapore, and over 30 other countries on six continents. By the end of
the epidemic, over 8000 cases were reported with an overall mortality
rate of approximately 10% (CDC, 2003). Although the precise origin of
the virus has not been elucidated, evidence suggests that the virus
likely was transmitted from bats in China through an intermediate
host such as the masked palm civet to humans (Lau et al., 2005; Li
et al., 2005; Ren et al., 2006).
The predominant mechanism for transmission is via airborne
droplets, although isolation of virus from feces and urine may suggest
additional routes of transmission (Chan et al., 2004a; Poon et al.,
2004). Following inoculation, the virus undergoes an incubation
period of 2–14 days (Chan et al., 2004b). Patients subsequently
present with ﬂu-like symptoms, fever, malaise, nonproductive cough,
and progressive respiratory deterioration, typically with involvement
of both lungs (Cheng et al., 2007; Gu and Korteweg, 2007). Patientsl rights reserved.often presented with watery diarrhea and hepatic dysfunction; 20–
30% of patients developed respiratory failure and requiredmechanical
ventilation.
Mortality in patients under 60 years of age was approximately
6.8%; however, disease severity was signiﬁcantly increased in elderly
populations with the mortality rate among individuals above 60 years
of age approaching 50%, likely due to an ineffective antiviral immune
response. Disease severity was shown to correlate with the early onset
of neutralizing antibody responses; the presence of neutralizing
antibody within the ﬁrst two weeks of illness was associated with
increased risk of mortality (Ho et al., 2005; Zhang et al., 2006).
Recovering patients continued to increase serum neutralizing anti-
body concentrations, peaking at approximately day 20, whereas fatal
cases demonstrated dramatically reduced neutralizing antibody after
day 15 of symptom onset (Zhang et al., 2006). This suggests that
sustainable levels of neutralizing antibody are correlated with
recovery of SARS-CoV-infected patients.
Since the identiﬁcation of the virus that causes SARS, numerous
animal models have been described in attempts to evaluate virus
replication, pathogenesis, and immunopathology. Animal models
described to date include several inbred mouse strains, hamsters,
civet cats, ferrets, cats, or nonhuman primates (Fouchier et al., 2003;
Glass et al., 2004; Greenough et al., 2005; Hogan et al., 2004; Lawler
et al., 2006;Martina et al., 2003;McAuliffe et al., 2004; Qin et al., 2005;
Fig. 1. Cyclophosphamide treatment results in immunosuppression of Syrian golden
hamsters. (A) White blood cell (WBC) counts per mm3 from saline or CP-A treated
hamsters were determined in uninfected (mock) or rSARS-CoV infected animals. Data
points are from n=1mock infected, and n=2–6 for all other samples. TheWBC counts in
saline-treated, mock infected animals did not change signiﬁcantly over the course of the
experiment. The average and standard error are graphed. (B) Complete WBC counts per
mm3 at days-1 and 19 pi from saline or CP-D treated hamsters infected with rSARS-CoV.
The average and standard error are graphed. (C) Serum neutralizing antibody titers from
saline or CP-treated hamsters either mock infected or infected with the indicated
recombinant SARS-CoV. Serum was collected from animals at days 19 and 42 pi, heat
inactivated, and serial dilutions were assayed for neutralizing capacity against 100
TCID50 of SARS-CoV. Data represent mean neutralizing titers.
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2004; ter Meulen et al., 2004;Wu et al., 2005). The timecourse of virus
replication in these small animal models is signiﬁcantly more rapid
than that observed in human infections (Roberts et al., 2008) and no
model fully reproduces the clinical illness or the pathology observed
in humans. The need exists for a useful small animal model that more
closely mimics human disease.
SARS-CoV infection of Syrian golden hamsters leads to viral
replication in the lungs and nasal turbinates, transient viremia and
extrapulmonary replication in the spleen and liver (Roberts et al.,
2005b). Primary hamster tracheobronchial epithelial cell cultures
support higher virus replication in comparison to similar murine
cultures, suggesting an increased susceptibility of hamster cells to
SARS-CoV infection (Sims et al., 2005). Histopathological evidence of
disease is evident in hamster tissues, with cellular necrosis,
pronounced interstitial inﬂammation, focal consolidation in pulmon-
ary tissues, and loss of ciliated epithelial cells being prominent features
(Roberts et al., 2005b); however, there is limited morbidity and no
mortality associated with infection. Increasing the severity of disease
in the hamster model may provide a useful tool for study of SARS-CoV
pathogenesis, antiviral drug testing, and for analysis of mutant viruses
deleted of one or more of the eight viral accessory genes.
Here, we report a cyclophosphamide (CP)-induced immunosup-
pressed Syrian golden hamster model for SARS-CoV infection.
Cyclophosphamide, a bifunctional alkylating agent, has been shown
to cause lymphopenia, suppress B-cell activity and activation, and
suppress regulatory T-cell function (Cupps, et al., 1982; Ikezawa et al.,
2005; Polak and Turk, 1974; Zhu et al., 1987). CP has been utilized in
various animal models for virus infection analysis, often increasing
the morbidity and mortality observed in virus-infected animals
(Blandford and Charlton,1977; Genovesi and Peters,1987; Kercher and
Mitchell, 2000; Kong et al., 2005; Mateo et al., 2006; Sidwell et al.,
2003; Smee et al., 1991). Recently, CP-induced immunosuppression of
Syrian golden hamsters was shown to enhance adenovirus replication
and pathology, and permitted the efﬁcacy testing of a broad-spectrum
antiviral, CMX001 (Toth et al., 2008).
Treatment of hamsters with CP augmented virus-induced pathol-
ogy and replication of recombinant SARS-CoV (rSARS-CoV) in tissues
including lung, spleen, liver, kidney, and heart. Infected animals
displayed high morbidity andmortality over approximately 30 days in
a manner dependent on the dosage regimen of CP. A similar infection
and pathogenesis pattern was observed after infection with rSARS-
CoV mutants defective for the expression of accessory proteins ORF7a
and ORF7b suggesting the functions of these proteins are not required
in this model. Therefore, we propose infection of CP-treated hamsters
as a more rigorous test of in vivo virus replication and virulence than
that provided by existing animal models.
Results
Cyclophosphamide induced immunosuppression in hamsters
To examine the effect of CP on the severity of rSARS-CoV disease in
hamsters, groups of animals were assigned to either saline or one of
four different CP regimens (Table 1). The four regimens were utilized
to determine dose- and time-dependent effects of CP treatment on theTable 1
Cyclophosphamide dosing regimens
Regimen 1st dose Subsequent doses
Saline 0.8 mL saline at day-5 0.8 mL saline every 4 days
CP-A 70 mg/kg CP at day-2 50 mg/kg CP every 4 days
CP-B 140 mg/kg CP at day-5 100 mg/kg CP every 4 day
CP-C 140 mg/kg CP at day-2 100 mg/kg CP every 4 day
CP-D 140 mg/kg CP at day-5 100 mg/kg CP every 3 day
CP was administered intraperitoneally.s
s
sseverity of disease. Animals were given a loading dose followed by
maintenance doses at speciﬁed intervals to maintain immunosup-
pression. To monitor the effect of treatments, total white blood cell
counts measured in blood from mock infected animals or rSARS-CoV
infected animals treated with saline, CP-A, or CP-D prior to infection
and at various times through the study (Figs. 1A,B). Decreased white
blood cells counts in animals treated with CP conﬁrmed the
immunosuppressive activity of the treatment regimens.
Animals were infected intranasally with 103 TCID50 of rSARS-CoV,
rSARS-CoV GFPΔORF7ab (a virus encoding GFP in place of the gene 7
open reading frame), or rSARS-CoV ΔORF7ab (a virus encoding a
deletion of the gene 7 open reading frames) at day 0 (Schaecher et al.,
2007b; Yount et al., 2005). Saline-treated animals demonstrated
elevated total WBC counts and lymphocytosis that peaked on day 9
postinfection (pi), and returned to near baseline levels by day 19 pi
(Fig. 1A). Treatment with the most mild CP regimen, CP-A, resulted in
signiﬁcant immunosuppression with animals demonstrating lower
initial WBC counts after virus infection, when compared to saline-
314 S.R. Schaecher et al. / Virology 380 (2008) 312–321treated animals (Fig. 1A). Animals treated with CP-D had depressed
total WBC counts at day 1 compared to saline-treated animals with
mean WBC counts of 1380±346 and 8590±1346 WBC/mm3, respec-
tively (Fig.1B). By day 19 pi, meanWBC counts in CP-D treated animals
dropped to 400±82 WBC/mm3 compared to near baseline levels of
9060±1653 WBC/mm3 in saline-treated animals.
SARS-CoV speciﬁc serum antibody response
To further conﬁrm immunosuppression and analyze adaptive
immune responses to rSARS-CoV, serum neutralizing antibodiesFig. 2. Daily mean weight and survival of saline and cyclophosphamide treated hamsters inf
regimen speciﬁed in Table 1 and inoculated intranasally with either saline (A,B) or 103 TC
Individual animals were weighed and data was normalized to animal weight on day 0 (A,C,
mock or CP-treated animals infected with each virus is shown (B,D,F,H). Black line, saline trspeciﬁc for SARS-CoV were quantiﬁed on days 19 and 42 pi (Fig. 1C)
using a virus neutralization assay. Saline-treated animals developed a
high neutralizing antibody titer by day 19 pi with no signiﬁcant
difference observed between animals infected with different rSARS-
CoV viruses. In contrast, little or no neutralizing antibody was
detected in CP-D treated animals at day 19 pi. At day 42 pi, animals
treated with CP-A had detectable neutralizing antibody responses to
both viruses; however, mean neutralizing titers were 40% lower than
those observed with saline-treated animals (1:4398±2008 and
1:2639±1244, respectively). No neutralizing antibody was detected
in uninfected animals or virus-infected animals treated with CP-Bected with rSARS-CoV. Groups of 3 golden Syrian hamsters were dosed with CP per the
ID50 of rSARS-CoV (C,D), rSARS-CoV GFPΔORF7ab (E,F), or rSARS-CoV ΔORF7ab (G,H).
E,G). Data represent average normalized weight and standard error. Percent survival of
eatment; yellow line, CP-A; green line, CP-B; blue line, CP-C; red line, CP-D.
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ing antibody titer).
Clinical manifestations and mortality
Animals were monitored for morbidity and mortality (Fig. 2)
over the course of approximately 36 days. Mock infected animals
treated with any of the CP regimens demonstrated no signiﬁcant
weight loss or overt clinical illness compared to saline-treated,
uninfected hamsters (Fig. 2A). With the exception of two out of six
CP-D treated animals, no mortality was observed (Fig. 2B),
indicating that CP treatment for less than 40 days had little impact
on viability.
As observed previously (Roberts et al., 2005b; Schaecher et al.,
2007b), SARS-CoV infection of hamsters resulted in minimal clinical
illness and transient or no weight loss between days 5–7 pi (Figs. 2C,E,
G). No mortality was observed in saline-treated hamsters (black line)
infected with any virus. Virus infection of CP-A treated animals
(yellow line) resulted in modest weight loss coupled with modest
clinical symptoms (fur rufﬂing, decreased activity) compared to virus-
infected, saline-treated hamsters, but resulted in no increase in
mortality. In contrast, infection of CP-B (green line), CP-C (blue line),
and CP-D (red line) treated animals resulted in an increased weight
loss and mortality. Two of 12 CP-B treated and infected animals
survived beyond day 28 and demonstrated some clinical improve-
ment and weight gain. Infected animals treated with CP-C or CP-D
progressively lost weight throughout approximately 30 days; no
statistically signiﬁcant difference in weight loss was observed among
the treatment groups. Infection with viruses bearing disruptions ofFig. 3. SARS-CoV titers in tissues from immunosuppressed hamsters. (A) CP-B treated hamst
times pi, and virus titers were measured in designated tissues. Open bars represent saline-tr
were infected intranasally with either rSARS-CoV or rSARS-CoV ΔORF7ab virus. Animals wer
bars represent saline-treated animals; hashed bars represent CP-D treated animals. (C)
GFPΔORF7ab. Moribund animals were sacriﬁced and virus titers weremeasured in the indica
CP-C, and CP-D were 26.0 (n=2), 31.3 (n=3), and 25.3 (n=3), respectively. Mean days to deat
26.5 (n=2), 31.0 (n=3), and 27.0 (n=3), respectively. TCID50 limit of detection=4.64×102 TCID
Moribund animals were sacriﬁced along with uninfected CP-D and age-matched saline-treate
animals were determined by TCID50.assay, and presented as means and standard error.accessory gene 7 led to morbidity and mortality similar to that seen
with wild-type virus, indicating that the disruption of gene 7 did not
signiﬁcantly alter virulence in this animal model.
Tissue tropism and virological analysis
Tissues were analyzed at various times pi for virus titers. Lungs
from saline and CP-A treated animals contained high virus titers as
early as day 2 pi, and titers remained high through day 5 (data not
shown). By day 9 pi, saline-treated animals had cleared detectable
virus from lung tissues while two of three CP-A treated animals
continued to have high lung viral titers out to day 19 pi. No
extrapulmonary virus was detected by TCID50 analysis in saline-
treated animals but virus titers were detected in several liver tissues
harvested from CP-A treated, infected animals at days 5 and 9 pi (data
not shown). Virus was not detected in any other tissues from CP-A
treated animals.
Tissues from CP-B treated animals were analyzed at days 2, 5,
and 9 pi (Fig. 3A). Lung titers in both saline and CP-B treated
animals were high on days 2 and 5. No virus was detected in the
lungs of saline-treated animals after day 5 pi; however, CP-B treated
animals were unable to clear virus from the lung and titers
remained high at day 9. Progressively increasing virus titers were
detected in the liver and spleen of CP-B treated animals but not
saline-treated animals.
High virus titers were present in lung, liver, spleen, and kidney
tissues on day 19 pi in CP-D treated animals but no virus was detected
in saline-treated animals (Fig. 3B). The presence of virus titers in
kidney tissues is signiﬁcant, as SARS-CoV has been detected in theers were infected intranasally with the indicated rSARS-CoV, sacriﬁced at the indicated
eated animals; hashed bars represent CP-B treated hamsters. (B) CP-D treated hamsters
e sacriﬁced at day 19 pi and virus titers were determined in the indicated tissues. Open
CP-B, CP-C, or CP-D treated hamsters were infected with rSARS-CoV or rSARS-CoV
ted tissues. Mean days tomoribundity for rSARS-CoV infected animals treatedwith CP-B,
h for rSARS-CoV GFPΔORF7ab infected animals treated with CP-B, CP-C, and CP-D were
50/mL (D) CP-D treated hamsters were infected with rSARS-CoV or treated with saline.
d animals. Virus titer was determined in heart tissue. In all panels, virus titers from n=3
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Xu et al., 2005). No signiﬁcant difference in virus titer was observed
betweenwild-type and ORF7 deletion viruses in saline or CP-D treated
animals.
Tissues harvested from moribund animals treated with CP-B, CP-C,
and CP-D revealed high virus titers in the lungs, liver, spleen, and
kidneys (Fig. 3C). All three treatments allowed for equivalent levels of
virus replication. No signiﬁcant difference was observed between
rSARS-CoV and rSARS-CoV GFPΔORF7ab with respect to infectious
virus titers in lung, liver, and kidney tissues (PN0.05). The rSARS-CoV
GFPΔORF7ab virus-infected hamsters appeared to have higher virus
titers in the spleen, but the difference was not statistically signiﬁcant
(P=0.085). Finally, heart tissues were analyzed for viral titers in saline-
treated and moribund CP-D treated animals infected with rSARS-CoV
(Fig. 3D). No virus was detected in hearts from saline-treated, infected
animals; however, high viral titers were observed in the heart tissues
from CP-D treated animals. Although the tissue speciﬁc expression of
ACE2 (the cellular receptor for SARS-CoV) has not been determined in
hamsters, ACE2 is expressed in heart, kidney, and testes in humans
(Donoghue et al., 2000; Tipnis et al., 2000). The high viral titers in the
hearts of these animals suggest that ACE2 is also present in heart
tissues of hamsters. Of note, heart pathology has also been observed in
human tissues from fatal SARS cases, including cardiac edema and
atrophy of myocardial ﬁbers (Chong et al., 2004; Ding et al., 2003;
Gu et al., 2005; Lang et al., 2003).Table 2
Histologic changes associated with cyclophosphamide
Tissue Diagnosis Group
Sacriﬁce day
Virus
CP-D
Severity
Bone marrow, femur Number examined
No signiﬁcant lesions
Atrophy, hematopoietic Minimal
Mild
Moderate
Marked
Bone marrow, sternum Number examined
No signiﬁcant lesions
Atrophy, hematopoietic Mild
Moderate
Hyperplasia, megakaryocytic Mild
Lymph node, mandibular Number examined
No signiﬁcant lesions
Depletion, lymphoid Mild
Moderate
Edema Mild
Moderate
Histiocytosis, sinus Mild
Hemorrhage, acute Mild
Lymph node, mesenteric Number examined
No signiﬁcant lesions
Depletion, lymphoid Mild
Moderate
Hemorrhage, acute Mild
Histiocytosis, sinus Moderate
Edema Mild
Ovary Number examined
No signiﬁcant lesions
Mineralization Minimal
Delayed development Mild
Moderate
Spleen Number examined
No signiﬁcant lesions
Depletion, lymphoid Moderate
Marked
Vagina Number examined
No signiﬁcant lesions
Vaginitis, necrotizing Moderate
MarkedCyclophosphamide induced histopathology
A summary of histopathology due to CP treatment is shown in
Table 2. At day 19 pi, administration of CP alone (CP-D) or in
conjunction with virus challenge was associated with mild to marked
hematopoietic atrophy in the bonemarrow (femur and sternum), mild
to moderate lymphoid depletion in the mandibular and/or mesenteric
lymph nodes, moderate to marked lymphoid depletion in the spleen,
and mild to moderate follicular atresia in the ovary, well-known
consequences of CP administration in rodents (Jarrell et al., 1987).
Atrophy of hematopoietic and lymphoid tissues is consistent with the
chemotherapeutic and immunosuppressive pharmacology of CP.
Hematopoietic atrophy was also evident in the bone marrow of CP-D
treated and infectedanimals onday5pi, butwasnot evident onday2pi.
Two instances of necrotizing vaginitis were observed in hamsters
treated with regimen CP-D; one of these was virus-infected and one
was not. Since the incidence of this ﬁnding was low, a deﬁnitive
relationship to CP administration was not certain; however, the
ﬁnding is consistent with opportunistic bacterial infection following
immunosuppression by CP.
Histopathological ﬁndings in cyclophosphamide treated, infected animals
Histopathological ﬁndings in saline-treated, rSARS-CoV infected
animals were generally consistent with those previously described1 2 3 4 5 6 Control Control
2 2 5 5 19 19 19 19
+ + + + + + − −
− + − + − + − +
0 0 0 0 2 2 2 2
2 0 2 0
1
1 1
1
2 2 2 2 2 2 2 2
2 2 2 0 2 0 2 0
2 1
2 1
0 0 0 0 2 2 2 2
2 0 2 0
1 2
1
2 2
2 1
1
0 0 0 0 2 1 1 2
2 0 1 0
2
1
1
0 0 0 0 2 2 2 2
2 0 2 1
1
1
2
0 0 0 0 1 2 2 1
1 0 1 0
1
1
0 0 0 0 2 2 2 2
2 1 2 1
1
1
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animals resulted in increased severity of histopathological ﬁndings in
pulmonary and extrapulmonary tissues (summarized in Table 3).
Lung
At day 19 pi, chronic bronchointerstitial pneumonia of mild to
moderate severity was observed in each of the hamsters infected with
rSARS-CoV following immunosuppression with CP (Fig. 4A panel iii).
Lesions were characterized by the presence of multifocal inﬁltrations
of a mixed population of macrophages and neutrophils with lesser
numbers of lymphocytes and plasma cells. Areas of ﬁbrosis and
hyperplasia of alveolar epithelial cells were frequently observed.
Inﬁltration was centered at the junction between distal bronchioles
and alveoli. At day 19 pi, this change was not present in the untreated,
rSARS-CoV infected animals (Table 3).
Examination of lungs from animals given rSARS-CoV and CP at
earlier times pi revealed the presence of moderate subacute
bronchointerstitial pneumonia in one of two animals sacriﬁced at
day 5 pi (Table 3; Fig. 4A panel ii); there were no meaningful changes
present at day 2 pi. Histologically, the lesions were similar to the day
19 lesions in distribution, but lacked conspicuous ﬁbrosis. Instead,
hyperplasia of alveolar epithelial cells was a prominent feature at this
earlier time point. Similar microscopic changes were also present in
the lungs of both rSARS-CoV infected animals not treated with CP at
day 5 (Table 3); no lesions were observed at day 2 pi.
Subacute inﬂammation of minimal severity was recorded for many
animals in most treatment groups. Although this change was not
observed in the small day 19 control groups, similar ﬁndings are
extremely common in the lungs of hamsters of this age. Therefore, this
change is not considered to represent a consequence of either rSARS-
CoV or CP administration.
Heart
At day 19 pi, multifocal subacute myocardial inﬂammation of
minimal severity was present in the hearts of two animals given rSARS-
CoV and CP but not in saline-treated, infected animals (Fig. 4B; Table 3).
This change consisted of inﬁltration by a mixed population of
neutrophils, lymphocytes and macrophages occasionally surrounding
degenerate or necrotic cardiacmyocytes (Fig. 4B). Similar changeswere
not observed in the hearts of animals from earlier sacriﬁce intervals.
Nasal cavity
Fibrinopurulent exudate was visibly adherent to the mucosal
surfaces at multiple levels of the nasal cavity in all animals inoculatedTable 3
Histologic changes associated with SARS-CoV
Tissue Diagnosis Group 1
Sacriﬁce day 2
Virus +
CP-D −
Severity
Heart Number examined 2
No signiﬁcant lesions 2
Inﬂammation, subacute Minimal
Kidney Number examined 0
No signiﬁcant lesions
Dilation, tubular Mild
Degeneration/necrosis, tubular Mild
Lung Number examined 2
No signiﬁcant lesions 0
Inﬂammation, subacute Minimal 2
Pneumonia, bronchointerstitial Mild
Moderate
Nasal turbinate Number examined 2
No signiﬁcant lesions 0
Exudate, ﬁbrinopurulent Minimal
Mild
Moderate 2with rSARS-CoV at days 2 and 5 pi (Table 3). There was no signiﬁcant
inﬂammatory cell inﬁltration within the submucosa of the nasal
turbinates. Mild degeneration of olfactory epithelium was present in
these regions. This change was present both in CP and saline-treated
groups on days 2 and 5, but was observed only in CP-treated animals
on day 19 pi (Fig. 4C).
Kidney
Dilation of renal cortical tubules or tubular degeneration and
necrosis was present in the kidneys of infected, CP-D treated animals
sacriﬁced on day 19 pi, but not in animals given only CP (Table 3). Each
change was mild in severity and affected one of two animals.
No histological changes were noted in the gastrointestinal tract or
the brain, therefore these tissues were not analyzed in subsequent
experiments.
Histopathological ﬁndings in moribund animals
Based upon initial observations, target organs for virus-asso-
ciated histopathology were considered to be the lung, heart, nasal
turbinates, and the kidney. To determine the signiﬁcance of these
ﬁndings to morbidity and mortality of rSARS-CoV infected immu-
nosuppressed hamsters, a follow-up study was conducted in which
four animals were immunosuppressed using the CP-D regimen and
inoculated with 103 TCID50 of rSARS-CoV. Four animals given CP or
saline only were used as controls. Animals were carefully monitored
for evidence of moribundity or mortality; when observed, a
matched number of control animals were sacriﬁced for comparison.
From these animals, the following tissues were examined micro-
scopically: heart, lung, spleen, kidney, bone marrow, and nasal
turbinates (Table 4).
One rSARS-CoV infected, CP immunosuppressed animal was found
dead on day 14 pi. Tissues from this animal exhibited changes
comparable to those described above; however, this animal also had
marked focal myocardial infarction with necrosis and bacteria,
consistent with a septic myocardial infarct. Septicemic cardiac disease
was interpreted as the cause death in this animal, and was likely
secondary to immunosuppression by CP.
As with the initial study, CP treatment in the presence or absence
of viral inoculation was associated with hematopoietic atrophy in the
bone marrow and lymphoid depletion in the spleen.
In rSARS-CoV infected hamsters, inﬂammatory changes similar to
those described above in the heart were present in all animals (Table 4).
Histologically, inﬂammatory changes were more severe than those2 3 4 5 6 Control Control
2 5 5 19 19 19 19
+ + + + + − −
+ − + − + − +
2 2 2 2 2 2 2
2 2 2 2 0 2 2
2
0 0 0 2 2 2 2
2 0 2 2
1
1
2 2 2 2 2 2 2
1 0 0 0 0 2 2
1 1 2
1
2 1 1
2 2 2 2 2 2 2
0 0 0 2 0 2 2
1
1 1 1 1
1 1 1
Table 4
Histologic ﬁndings in moribund animals
Tissue Diagnosis Group 1 2 Control
Virus + − −
CP-D + + −
Severity
Bone marrow Number examined 4 4 4
No signiﬁcant lesions 0 0 4
Atrophy, hematopoietic Mild 4 3
Moderate 1
Heart Number examined 4 4 4
No signiﬁcant lesions 0 4 4
Epicarditis, subacute Marked 4 3
Inﬂammation, subacute Mild 1
Moderate 3
Infarction, myocardial Moderate 1
Kidney Number examined 4 4 4
No signiﬁcant lesions 0 4 3
Degeneration/necrosis, tubular Minimal 1
Mild 2
Moderate 1
Dilation, tubular Mild 1
Lung Number examined 4 4 4
No signiﬁcant lesions 0 2 4
Pneumonia, bronchointerstitial Moderate 1
Marked 3
Pleuritis, subacute Marked 1
Histiocytosis, alveolar Minimal 2
Nasal turbinates Number examined 4 4 4
No signiﬁcant lesions 0 4 4
Exudate, ﬁbrinopurulent Mild 2
Moderate 2
Spleen Number examined 4 4 4
No signiﬁcant lesions 0 0 4
Depletion, lymphoid Marked 4 4
Fig. 4. Histopathology of SARS-CoV infected hamsters. Hematoxylin and eosin (H and E)
stain of pulmonary and extrapulmonary tissues. (A) Histopathologic lesions in the lungs
of rSARS-CoV infected hamsters treated with CP-D. (i) Bronchoalveolar junction of
control animal lung. (ii, iii, iv) Temporal changes in the lung of hamsters at 5, 19, and
23 days pi, respectively. In animals sacriﬁced moribund (n=1 at day 23 pi and n=2 at
day 24 pi) (iv), changes were severe, widespread and frequently associated with
hemorrhage. (B)Myocardium sections of (i) uninfected and (ii) rSARS-CoV infected, CP-D
treated hamsters at 19 days pi. Subacute inﬂammation in the myocardium was present
in rSARS-CoV infected animals, as well as in those animals sacriﬁced moribund. (C)
Nasal turbinates of (i) uninfected and (ii) rSARS-CoV infected, CP-D treated hamsters
19 days pi.
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pi, severe pulmonary lesions were observed, representing an increasing
consolidation and histologic severity from lesions observed on day 19
pi. Therewas extensive pulmonary hemorrhage and edema in the lungs
of these animals (Table 4). All rSARS-CoV infected animals exhibited
minimal to moderate renal tubular degeneration and necrosis and
ﬁbrinopurulent exudation within nasal turbinates similar to that
described above (Table 4).
Discussion
The lack of a small animal model that more closely resembles
human SARS-CoV infection has restricted the study of SARS-CoV
pathogenesis, vaccine design, and analysis of antiviral therapies in
vivo. Pathological analysis of the respiratory tracts of SARS patients
revealed diffuse alveolar damage, hyaline membrane formation and
interstitial edema. Extrapulmonary pathology included splenic lym-
phocyte depletion and atrophy, acute tubular necrosis in kidneys,
neuronal edema and degeneration, heart edema and myocardial ﬁber
atrophy, and minor pathological changes in bone marrow, skeletal
muscle, adrenal and thyroid glands, and testes (reviewed in Gu and
Korteweg, 2007). Viral particles and viral genomes were detected in
numerous tissues and cell types including the respiratory epithelium,
circulating lymphocytes, monocytes, lymphoid tissues, intestinal
mucosal epithelium, renal distal tubule epithelial cells, neurons of
the brain, and macrophages in multiple organs (Gu et al., 2005). An
ideal small animal model would encompass many of the character-
istics of human infection, including severe pulmonary disease, spread
of virus to extrapulmonary organs and tissues, histopathology
reminiscent of human infection, overt clinical symptoms, a longer
time period of infection and mortality.
BALB/c and C57BL/6 mice have been predominantly utilized for
small animal infection studies. SARS-CoV inoculation in these mouse
strains demonstrates moderate replication in nasal turbinates and
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days 5–7 pi (Glass et al., 2004; Hogan et al., 2004; Roberts et al.,
2005a; Subbarao et al., 2004). Infected mice do not display overt
clinical disease and demonstrate no morbidity or mortality. An aged
BALB/c mouse model has been described that demonstrates some
observable morbidity including weight loss, rufﬂed fur, and increased
histopathological ﬁndings (Roberts et al., 2005a). No mortality was
observed. STAT1−/− 129SvEv mice were analyzed as a potential animal
model and displayed a prolonged infection period with extrapulmon-
ary spread to the liver and spleen, and histopathological ﬁndings of
acute interstitial pneumonia (Hogan et al., 2004), although no
mortality was reported. The ﬁrst murine models that demonstrated
severe disease and mortality utilized C57BL/6 and C57BL/6×C3H/HeJ
mice transgenic for human ACE2, the SARS-CoV cellular receptor
(McCray et al., 2007; Tseng et al., 2007). Infection of the transgenic
mice resulted in a severe and rapid progression of disease with 100%
mortality by day 7–8 pi. Virus replication was detected in several
organs with high virus titers in the brain by day 3. Although
potentially useful for pathogenesis studies, the severe and rapid
nature of disease coupled with the prominent, neurologic involve-
ment may constrain their usefulness as a small animal model for
SARS-CoV. Additionally, a mouse-adapted strain of SARS-CoV has been
generated via 15 serial passages through BALB/c mice (Roberts et al.,
2007). This virus is capable of causing severe disease in mice with
extrapulmonary spread; however, as with the transgenic ACE2 mice,
the disease is rapid causing death within 5 days of inoculation.
The results of this study demonstrate that CP-induced immuno-
suppression of Syrian golden hamsters signiﬁcantly increases the
severity of SARS-CoV disease. Although hamsters are permissive to
SARS-CoV infection, animals demonstrate minimal clinical illness and
weight loss, and no mortality is observed (Roberts et al., 2005b). The
use of CP to induce an immunosuppressed state results in a signiﬁcant
increase in viral pathology, increased weight loss, expanded tissue
tropism and a prolonged time frame for disease.
A low dose CP regimen (CP-A) led to prolonged virus replication in
the lungs, and other organs, but only moderate weight loss and no
mortality. Since the effects of CP are primarily on lymphoid cell
populations, this data suggests the involvement of this cell type in the
control and clearance of SARS-CoV in the lung. Increasing the CP dose
and frequency resulted in a signiﬁcant increase in pathology and
mortality. CP-B treatment resulted in an 83% mortality rate, whereas
100% of CP-C and CP-D infected animals died within approximately
30 days of rSARS-CoV infection. High virus titers were observed in
numerous tissues from the CP-B, CP-C, and CP-D treated animals,
including lung, liver, spleen, kidney, and heart.
Infection with rSARS-CoV was associated with acute ﬁbrinopuru-
lent exudation in the nasal cavity and renal tubular degeneration/
necrosis regardless of the presence or absence of CP immunosuppres-
sion. Additionally, rSARS-CoV infection following CP-D immunosup-
pression produced bronchointerstitial pneumonia which progressed
in severity over the duration of the experiment. Subacute inﬂamma-
tion of the ventricular myocardium was observed in immunosup-
pressed, rSARS-CoV infected animals, with increasing severity being
observed between days 19 and 23/24 pi. The latter changes (chronic
bronchointerstitial pneumonia and myocardial inﬂammation) likely
contributed to the severity of clinical disease necessitating sacriﬁce of
moribund animals 23–24 days pi. It is important to note that we did
not see pathology in the gastrointestinal tract or in the brain of any
SARS-CoV infected hamsters. SARS-CoV has been associated with
gastrointestinal tissue in human autopsies and mice expressing the
human ACE2 receptor show symptoms of encephalitis after SARS-CoV
infection. The signiﬁcance of SARS-CoV infectin of the brain and
gastrointestinal tract is not clear and remains an open area of
investigation.
Although this immunosuppressed model will not likely be useful
for vaccine studies, it may be of signiﬁcant utility in analysis of thevirulence of recombinant viruses and in assessing the efﬁcacy of
antiviral compounds or treatments. In this study, we have analyzed
the in vivo replication and pathogenesis of two recombinant SARS-
CoV strains with deletions of the ORF7ab region. rSARS-CoV ΔORF7ab
viruses can replicate with wild-type efﬁciency in vitro and in mouse
models of SARS-CoV infection (Dediego et al., 2008; Schaecher et al.,
2007b; Sims et al., 2005; Yount et al., 2005). Together these data
suggest that the SARS-CoV ORF7a and ORF7b proteins are not required
for viral replication in the small animal models described to date, but
may provide luxury functions in other host species. It will be
important to test a number of other recombinant viruses bearing
disruption of other accessory genes in the immunosuppressed
hamster model.
It is not clear if the increased pathology observed in CP-treated,
infected animals is due to increased virus replication, prolonged virus
replication or to increased damage from cytokines induced by the
infection. Reagents for cytokine analysis in hamsters are lacking but
this is clearly an important area of future research. The efﬁcacy of
antiviral or immunotherapies in protecting CP-treated hamsters from
SARS-CoV disease will be important to assess, as the increased virus
replication and spread of virus to extrapulmonary sites provides a
more rigorous test of treatment efﬁcacy.
Materials and methods
Cells
Vero (ATCC CRL-1586) cells were cultured in complete medium
(Dulbecco's modiﬁed Eagle medium containing 10% fetal bovine
serum [Atlanta Biologicals], 1 mM glutamine [Gibco], 1 mM sodium
pyruvate [Cellgro], 100 U/mL penicillin [Gibco], and 100 μg/mL
streptomycin [Gibco]). Cells were incubated in a 5% CO2 humidiﬁed
incubator at 37 °C.
Viruses
Recombinant SARS-CoVs were kindly provided by Ralph Baric,
University of North Carolina. Either recombinant, wild-type SARS-CoV
(rSARS-CoV), virus with GFP in place of the gene 7 coding region
(rSARS-CoV GFPΔORF7ab), or virus with the gene 7 region fully
deleted (rSARS-CoV ΔORF7ab) was used. Brieﬂy, nucleotides 27276 to
27643 (accession number A278741) were either deleted or replaced
with the ORF for GFP, and recombinant viruses generated as
previously described (Sims et al., 2005; Yount et al., 2003; 2005).
The viruseswere propagated and virus titers determined as previously
described (Nelson et al., 2005; Schaecher et al., 2007a). All infections
were performed in a biosafety level 3 laboratory using Institutional
Biosafety Committee approved procedures.
Cyclophosphamide treatment and infection of Syrian golden hamsters
Six to seven week-old Syrian golden hamsters (Charles River
Laboratories) were housed three per cage in a biosafety level 3 animal
facility. CP (Sigma) was dissolved in 0.9% saline with vigorous shaking
to make a stock solution of 21 mg/mL. Animals were injected
IP with 0.8 mL of saline or 0.2–0.8 mL of CP to the desired concen-
tration and per the dosing schedule detailed in Table 1 to maintain
immunosuppression.
Animals were acclimatized in the ABSL-3 biosafety containment
rack for at least 7 days, and then inoculated with PBS or 103 TCID50 of
virus in a total volume of 100 μL (50 μL into each naris). Hamsters were
weighed at the indicated times pi.
CP-induced immunosuppression was monitored by total white
blood cell (WBC) counts utilizing using a Pentra 60 Hematology
Analyzer (ABX Diagnostics, Montpellier, France) per the manufac-
turer's protocol for samples collected before virus infection. A
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collected after virus infection using a blood smear and modiﬁed
Wright's stain. Ten ﬁelds of cells were counted at a 10× magniﬁcation
per sample.
Hamsters were sacriﬁced on the indicated days pi, and virus
titers in homogenates of lung, kidney, liver, spleen, and heart
tissues were determined (Rowe et al., 2004b). Tissues were
weighed, complete medium was added to achieve a 10% weight
to volume (wt/vol) suspension, and homogenized using tissue
grinders (Fisher). After centrifugation at 3400 rpm for 10 min, the
supernatants were removed and analyzed by TCID50 assay. All
procedures were performed under protocols approved by the
Institutional Biosafety and the Institutional Animal Care and Use
Committees.
Neutralizing antibody analysis
Animal sera was collected from infected animals at days 19 and
42 pi and assayed for the presence of anti-SARS-CoV neutralizing
antibodies essentially as described by others (Subbarao et al., 2004).
Brieﬂy, serum was heat inactivated at 55 °C for 30 min. Two-fold
dilutions of inactivated sera were mixed in complete media to a ﬁnal
volume of 100 μL per well and 100 TCID50 of SARS-CoV per 100 μL
sera-containing media was added. The antisera-virus suspension
was pre-incubated at 25 °C for 30 min. 100 μL was added to each of
6 wells of Vero cell monolayers in a 96 well plate per serum
dilution. Cells were ﬁxed with 1% formaldehyde 4 days pi, stained
with Napthol Blue-Black (Sigma), and analyzed for cytopathic effect.
The dilution of serum that prevented cytopathic effect in 50% of
wells was calculated using the Reed-Muench formula (Reed and
Muench, 1938).
Histopathology
Formalin-ﬁxed tissues were embedded in parafﬁn and 4–5 μm
thick sections were generated with a microtome and stained with
hematoxylin and eosin. The CP-D treatment regimen was used for all
histopathological studies. The following tissues were harvested at day
19 pi: adrenal gland, aorta, bone (femur), bone (sternum), bone
marrow (femur), bone marrow (sternum), brain, cecum, cervix, colon,
duodenum, esophagus, eye, gall bladder, Harderian gland, heart,
ileum, jejunum, kidney, larynx, liver, lung, mammary gland, mandib-
ular lymph node, mesenteric lymph node, nasal cavity (3 levels), optic
nerve, ovary, pancreas, parathyroid, pituitary gland, rectum, salivary
gland, skeletal muscle, skin, spinal cord, spleen, stomach, thymus,
thyroid, tongue, trachea, urinary bladder, uterus, and vagina. Tissues
from two animals per conditionwere assessed. Based on ﬁndings from
this full survey of tissues, tissues including bone marrow (sternum or
tibia), heart, lung, kidney, spleen and nasal cavity (2 animals per
group) were examined at the indicated days postinfection in
subsequent experiments.
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